-
NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor
Next Generation Intratumoral Technology Targets Diffuse Intrinsic Pontine Glioma Investigational New Drug Enabling Studies are Underway with Planned Clinical Trial to Begin Late 2026 FORT WORTH, Texas, Dec. 11, 2025 /PRNewswire/ — NanOlogy, LLC, a
-
Give the Gift of Health This Holiday Season with the jscreen jGift
ATLANTA, Dec. 11, 2025 /PRNewswire/ — This holiday season, jscreen introduces the jGift, a simple and meaningful way to give the gift of health. The jGift makes it easy for anyone to share the benefits of genetic
-
Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001
Equity-backed commitment dramatically de-risks pivotal program, boosts licensing appeal, and strengthens commercialization readiness. HUNTINGTON, N.Y., Dec. 11, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a clinical-stage biotechnology company pioneering novel anti-inflammatory combination therapeutics, today announced a transformative
-
Mercury Bio Announces Appointment of Casey Perkins as Vice President of Corporate Strategy & Business Development
SANTA FE, N.M., Dec. 9, 2025 /PRNewswire/ — Mercury Bio, a company advancing intracellular delivery for central nervous system (CNS) therapeutics through its proprietary yEV™ platform, is pleased to announce the appointment of Cassandra “Casey” Perkins as Vice
-
Yenos Analytical Launches the Yenos Test, First-of-its-Kind Multi-Cancer Early Detection Urine Test
-Only MCED test to use a urine sample collected at home instead of blood draw.-Only MCED to detect stage I/II cancers with 97% sensitivity and 97% specificity.-Offered as a laboratory-developed test at $749-Nationwide access enabled
-
Sen-Jam Pharmaceutical Appoints Global Life Sciences Leader Rute Fernandes as Executive Advisor to Accelerate Commercialization Pathways
HUNTINGTON, N.Y., Dec. 9, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics for inflammation-driven conditions, today announced the appointment of Rute Fernandes as Executive Advisor to support commercialization strategy, scenario planning,
-
Korea University Researchers Develop Ultrasensitive Method to Detect Low-Frequency Cancer Mutations
SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ — MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero off-target activity. By
-
Immorta Bio Reports Reduction of Tumors in Validated Models of Lung, Brain, Pancreatic, and Breast Cancers Using Anti-Aging Vaccine “SenoVax™”
Scientific Longevity Company Collaborates with Major Academic Institutions to Remove Tumor Defense Mechanisms and Help Defeat Cancer in a Non-Toxic Manner MIAMI, Dec. 4, 2025 /PRNewswire/ — Immorta Bio today announced the publication of a
-
Dicom Systems Processes 124 Billion Medical Images Annually and Achieves ISO 27001 Certification, CE Mark, Expands Digital Pathology and Reseller Partnerships
DANVILLE, Calif., Dec. 3, 2025 /PRNewswire/ — Dicom Systems, a leader in enterprise imaging interoperability and workflow orchestration, has reached a significant milestone, processing 124 billion medical images (547.9 million studies) annually, an increase of
-
“GlobalMedKz Has Become a Bridge Between East and West in Medicine” — Kristina Krivets on the Success of the 2025 Exhibition
ASTANA, Kazakhstan, Dec. 3, 2025 /PRNewswire/ — The international exhibition GlobalMedKz: Global Health, Innovations and Medical Tourism concluded with remarkable success at the EXPO International Exhibition Center in Astana, reinforcing Kazakhstan’s leadership role in global
